Clinical Trial

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

Study acronym: NIRVANA-1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +/-bevacizumab.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-01-05; most recent amendment 2026-04-08.
Status change: Not Yet Recruiting → Recruiting 2022-02-02
Trial Details
NCT Number NCT05183984
Lead Sponsor ARCAGY/ GINECO GROUP
Conditions Ovarian Cancer
Enrollment 390 participants
Start Date 2022-02-01
Primary Completion 2027-02 (estimated)
Study Completion 2032-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-13